Genovis
49,7 SEK -2,55 %1.637 investorer følger denne virksomhed
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Omsætning
102,39 mio.
EBIT %
8,09 %
P/E
261,58
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GENO
Daglig lav / høj pris
49,15 / 51
SEK
Markedsværdi
3,25 mia. SEK
Aktieomsætning
2,56 mio. SEK
Volumen
51 t
Finanskalender
Delårsrapport
24.08.2023
Delårsrapport
15.11.2023
Årsrapport
15.02.2024
Viser Alle indholdstyper